Form 4: Iteos Therapeutics Director Acquires Stock Options
SEC Form 4 Filing
Director Timothy Van Hauwermeiren acquired 24,200 stock options in Iteos Therapeutics, Inc. on June 11, 2024.
Summary
- On June 11, 2024, Timothy Van Hauwermeiren, a director of Iteos Therapeutics, Inc., acquired 24,200 stock options.
- The exercise price of these options is $16.32.
- The options become exercisable on June 11, 2025, and expire on June 11, 2034.
- Following the transaction, Van Hauwermeiren directly owns 24,200 derivative securities.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a routine transaction. The acquisition of stock options by a director is generally viewed as a positive, but it's not a major event.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This is a standard Form 4 filing, reflecting a change in beneficial ownership of securities. It's common for directors and officers to receive stock options as part of their compensation.
Stakeholder Impact
- The acquisition of stock options by a director could have a slightly positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 06/11/2024 | Date of transaction: Director acquired stock options. |
| 06/11/2025 | Date exercisable: Stock options become exercisable. |
| 06/11/2034 | Expiration date: Stock options expire. |
| 06/13/2024 | Date of signature. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.